CHC™ Technology

The CHC™, Corline Heparin Conjugate, is based on pre-assembled aggregates of more than 20 heparin molecules. The conjugate is used as stand-alone pharmaceutical compound, the case of Renaparin™, or as part of a larger complex like for Cytoparin™ or CHS™ medical device coatings.

The inner lining of a blood vessel wall is the only known fully blood compatible surface. But by mimicking nature itself, Corline's CHC™ technology comes a close second.

Heparin

A naturally occurring biomolecule in the body, heparin is routinely used in surgery as an anticoagulant pharmaceutical to prevent harmful blood clotting.

Heparin has important anti-coagultive and anti-inflammatory effects and is known to attract a range of growth factors, for example vasculature promoting factors. Due to its specific features, surface coating with immobilized heparin dramatically improves transplant and implant blood and biocompatibility and may also lead to better engraftment of transplanted organs and cells. Corline is leading the field of safe biological product coating; the know-how of treating functional heparin onto living cells and tissue without compromising their viability is unprecedented.

read moreread less

CHC™ Evidence

A portfolio of over 60 scientific publications reports CHC™ pre-clinical and clinical outcome data in various medical disciplines and for different indications.

We are constantly adding to this fundament of scientific evidence. Contact us to receive an updated CHC™ publications list.

read moreread less

Regenerative Medicine

To advance new concepts of Regenerative Medicine, solutions improving graft tolerance and therefore patient safety are more sought after than ever before. Front-line technology enables to trick the patient’s immune response into recognizing foreign material as its’ own, and speeds up the healing process.

Corline is leading the field of safe biological product coating; the know-how of treating functional heparin onto living cells and tissue without compromising their viability is unprecedented.

Renaparin™ - Kidney Transplantation

Every year over 70,000 patients, of which 33,000 in the EU and USA, receive a kidney transplant to treat end stage renal failure.

During preservation prior to surgery, the kidney lacks natural blood flow which can lead to ischemia and when connected to the recipient blood flow, this in turn leads to ischemia-reperfusion injury (IRI). IRI poses a major challenge in many thrombotic conditions and in whole organ transplantation. According to public information, IRI results in delayed graft function in up to 40 % of transplants and may also lead to acute kidney failure. 

Due to the alarming shortage of organs available for transplantation, the prevention of IRI has become a top priority for the transplantation community. A superior treatment strategy would have the potential to extend current donor criteria, thus increasing the number of transplantable organs.

Corline’s Renaparin™ is administered by flushing the vessel system of the kidney ex vivo prior to transplantation, and repairs the damaged blood vessel system. RenaparinTM thus protects kidneys from the innate immune response and has been shown to significantly decrease reperfusion injury in pre-clinical models.

Corline® has been granted orphan drug designation in the EU for Renaparin™.

read moreread less

Cytoparin™ - Cell Therapy/Diabetes Type 1

Patients with severe types of diabetes type 1 have difficulties controlling blood sugar levels, despite modern monitoring equipment and strict insulin regimes.

Islet transplantation is a novel treatment of the disease currently undergoing clinical trials, where isolated islets cells from a donor pancreas are introduced into the patient, to restore glucose level regulation.

Diabetes is a global disease and the WHO projects that “Diabetes will be the 7th leading cause of death in 2030”. Between 1999-2004, 471 patients with type 1 diabetes received islet transplants at 43 institutions worldwide. Registered clinical studies currently include more than 1,000 patients.

During the procedure, allogeneic donor islets are infused into the patient's liver. An adverse immune response and inflammation reaction risks reducing the survival of the infused cell mass by 50-80 %. Due to this destruction of cell mass 2,7 donors is required to successfully treat one patient.

CytoparinTM functions as a protective layer shielding islets from the innate immunity response and reduces coagulation and complement activation. By so doing, it has the potential to significantly improve cell mass survival and thus transplant outcome and Corline's current goal is a 1-to-1 relationship between donors and patients.

Corline has obtained approval from the Swedish MPA to conduct clinical trials with CytoparinTM.

read moreread less

CHC™ - Soft Tissue Repair

In the treatment of soft tissue injuries, often a supporting mesh or matrix is introduced to improve stability of the repair site.

Typical applications are in extremity, rotator cuff, hernia and abdominal wall repair, but also in plastic surgery and facial reconstruction.

In complex and difficult to heal soft tissue injuries, a biologic mesh is generally preferred. Correctly designed and applied, such a mesh will support the body’s natural regeneration and subsequently be reabsorbed. Key to this beneficial effect is the prevention of an excessive inflammatory response, which can lead to detrimental encapsulation rather than healing and rapid growth of blood vessels into the matrix.

CHC™ coated collagen matrices have shown to reduce inflammation and successfully promote endothelial cell growth and revascularization in a collagen structure.

read moreread less

Medical Devices

When medical devices have blood contact, acute clot prevention is paramount and long-term negative effects of the foreign material on the body’s coagulation system need to be carefully managed.

CHS™ improves blood compatibility of almost any material used in conventional medical devices.

CHS™ Coronary Stents

A coronary stent is a metallic tube-shaped device, placed in the coronary arteries that supply blood to the heart, for the treatment of acute or threatened vessel closure during coronary angioplasty.

As the stent is an object recognized as foreign by the body, stenting risks to incite an immune response.

This may trigger cell proliferation and scar tissue formation, impairing a proper functioning of the stent. In addition, there is a high risk for blood clot formation at the site where the stent scrapes the arterial wall.

Corline uses its unique CHS™ surface technology on bare metal stents thus alleviating the clotting problem; Until today, more than 100,000 CHSTM stents have been successfully used to treat cardiovascular complications in patients.

read moreread less